Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial
Abstract Background Cerebral oxygenation monitoring may reduce the risk of death and neurologic complications in extremely preterm infants, but no such effects have yet been demonstrated in preterm infants in sufficiently powered randomised clinical trials. The objective of the SafeBoosC III trial i...
Main Authors: | Mathias Lühr Hansen, Adelina Pellicer, Christian Gluud, Eugene Dempsey, Jonathan Mintzer, Simon Hyttel-Sørensen, Anne Marie Heuchan, Cornelia Hagmann, Ebru Ergenekon, Gabriel Dimitriou, Gerhard Pichler, Gunnar Naulaers, Guoqiang Cheng, Hercilia Guimarães, Jakub Tkaczyk, Karen B. Kreutzer, Monica Fumagalli, Olivier Claris, Petra Lemmers, Siv Fredly, Tomasz Szczapa, Topun Austin, Janus Christian Jakobsen, Gorm Greisen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-019-3955-6 |
Similar Items
-
Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants
by: Mathias Lühr Hansen, et al.
Published: (2019-12-01) -
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial.
by: Anne M Plomgaard, et al.
Published: (2017-01-01) -
Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach
by: Markus Harboe Olsen, et al.
Published: (2021-07-01) -
Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III
by: Mathias Lühr Hansen, et al.
Published: (2020-04-01) -
Extremely Preterm Infant Admissions Within the SafeBoosC-III Consortium During the COVID-19 Lockdown
by: Marie Isabel Rasmussen, et al.
Published: (2021-07-01)